Table 2. Patient clinical and immunophenotypical characteristics of patients with DLBCL, NOS in relation to protein expressions.
| MYC | BCL2 | BCL6 | ||||||||
| Characteristic | All patients (n = 336) | Low (n = 166) | High (n = 170) | P | Low (n = 165) | High (n = 171) | P | Low (n = 215) | High (n = 121) | P |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||||
| LDH>ULN | 129 (38) | 50 (30) | 79 (46) | 0.002 | 58 (35) | 71 (42) | 0.230 | 84 (39) | 45 (37) | 0.734 |
| ECOG PS ≥2 | 51 (15) | 19 (11) | 32 (19) | 0.060 | 17 (10) | 34 (20) | 0.014 | 34 (16) | 17 (14) | 0.665 |
| Stage III/IV | 156 (46) | 70 (42) | 86 (51) | 0.122 | 75 (45) | 81 (47) | 0.725 | 108 (50) | 48 (40) | 0.062 |
| Extranodal sites ≥2 | 57 (17) | 29 (17) | 28 (16) | 0.807 | 27 (16) | 30 (18) | 0.773 | 39 (18) | 18 (15) | 0.444 |
| IPI score of 3–5 | 83 (25) | 33 (20) | 50 (29) | 0.043 | 36 (20) | 51 (29) | 0.056 | 59 (27) | 24 (20) | 0.121 |
| Immunohistochemical subgroups | ||||||||||
| CD5-positive | 15 (4) | 6 (4) | 9(6) | 0.658* | 5 (2) | 10 (7) | 0.001 * | 12 (6) | 3 (3) | 0.004 * |
| GCB | 90 (27) | 47 (28) | 43 (25) | 0.595# | 59 (36) | 31 (18) | <0.001 # | 45(21) | 45 (37) | 0.002 # |
| non-GCB | 231 (69) | 113 (68) | 118 (69) | 101 (62) | 130 (75) | 158 (73) | 73 (60) | |||
P values were derived from Pearson’s Chi-Square test. Bold font indicates significance. ULN, upper limit of normal.
*P value CD5+ vs. GCB vs. non-GCB.
#
P value GCB vs. non-GCB.